Christopher Nelson - Feb 6, 2024 Form 4/A Insider Report for QSAM Biosciences, Inc. (QSAM)

Role
EVP Corp Dev & General Counsel
Signature
/s/ Christopher Nelson
Stock symbol
QSAM
Transactions as of
Feb 6, 2024
Transactions value $
$0
Form type
4/A
Date filed
2/14/2024, 04:43 PM
Date Of Original Report
Feb 13, 2024
Previous filing
Jun 23, 2023
Next filing
May 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QSAM Common Stock Conversion of derivative security $26K +8.68K +5.01% $3.00* 182K Feb 6, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QSAM Series B Convertible Preferred Stock Conversion of derivative security -$26K 0 Feb 6, 2024 Common Stock 8.68K $3.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Correction to footnote: On February 13, 2024, the reporting person filed a Form 4 which inadvertently reported in footnote 1 that the date of the Exchange Agreements between the Issuer and all the Series B stockholders was 11/18/2023. It is hereby corrected that the Exchange Agreements were entered into between the dates of 10/16/2023 and 10/23/2023.